Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prevalence of germline T790M.

Published byΕύφημη Αντωνιάδης Modified over 5 years ago

Similar presentations

Presentation on theme: "Prevalence of germline T790M."— Presentation transcript:

1 Prevalence of germline T790M.
Prevalence of germline T790M. A, Querying a database of 31,414 unique cancer patients with plasma NGS results, 48 (0.15%) were found to carry a germline EGFR T790M mutation. Nonsquamous non-small cell lung cancer (NSCLC) was the dominant diagnosis in these patients. B, As compared to the population prevalence of germline EGFR T790M in a reference cohort (0.008%), there is a higher prevalence in subjects with nonsquamous NSCLC (0.34%) but not in subjects with other cancers (0.03%, P = 0.06), suggesting germline EGFR T790M is a risk variant for lung cancer. *, P < 0.05. Yuebi Hu et al. Clin Cancer Res 2017;23: ©2017 by American Association for Cancer Research

Download ppt "Prevalence of germline T790M."

Similar presentations

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey 07458 Lung Cancer and Gefitinib  Lung cancer statistics in the.

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.
The expression and signaling of FGFR3 in WM cells.

The expression and signaling of FGFR3 in WM cells.
Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene
Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.
Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms

Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms
New Patient Journeys in Non-small cell lung cancer

New Patient Journeys in Non-small cell lung cancer
Rearrangements of Gene A and Gene B

Rearrangements of Gene A and Gene B
Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Supplemental Figure 1 A B Alteration Time 1 (AF) Time 2 (AF)

Supplemental Figure 1 A B Alteration Time 1 (AF) Time 2 (AF)
Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.
T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference
Figure 4 Example of a patients with CUP

Figure 4 Example of a patients with CUP
Clonal evolution in Ewing sarcoma.

Clonal evolution in Ewing sarcoma.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Serum vs FNA:.

Serum vs FNA:.
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Similar presentations

Ads by Google